PROGRAM CHAIR
Prithviraj Bose, MD
Professor, Department of Leukemia
Co-Section Head, MPN Section
UT MD Anderson Cancer Center
Houston, Texas
Pankit Vachhani, MD
Associate Professor of Medicine
Chief – Leukemia service
Director – Strategic Outreach and Events
Medical Director – Clinical Research Unit (CRU)
University of Alabama at Birmingham
Birmingham, Alabama
PROGRAM OVERVIEW
This CME activity provides clinicians with evidence-based approaches to optimize management of anemia in myelofibrosis (MF). Participants will examine current guideline recommendations for sequencing anemia-directed therapies, review safety and efficacy data for approved and emerging agents, and evaluate patient characteristics predictive of benefit from early frontline anemia-sparing strategies. The program emphasizes individualized decision-making to improve outcomes, reduce toxicity, and deliver timely, patient-centered care across diverse clinical scenarios and treatment settings.
TARGET AUDIENCE
This program is designed to address the educational needs of the multidisciplinary hematology-oncology team, including hematologists, pathologists, nurses, and other multidisciplinary healthcare professionals working together to address the needs of patients with anemia due to MF.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Apply guideline recommendations for the management and sequencing of anemia-directed therapies for patients suffering from anemia associated with MF
- Integrate the safety and efficacy data for emerging and approved anemia targeting agents in MF to inform treatment strategies
- Assess patient characteristics that could predict benefit from early frontline anemia-sparing therapies in MF to provide appropriate and timely treatment
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtual activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtual activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
ACCME INNOVATION PARTNER DISCLAIMER
Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Prithviraj Bose, MD | Consulting Fee: Incyte, BMS, GSK, Sobi, Merck, Takeda, Sumitomo, Karyopharm, Ionis, Disc, Deciphera, Raythera, Geron, Cogent, Damora, Vyne, V6, Novartis, Pharma Essentia Fees for Non-CME/CE Services Received Directly from a Commercial Interest or its Agent: Incyte, GSK, Cogent, Novartis, Pharma Essentia Contracted Research: Incyte, BMS, GSK, Merck, Sumitomo, Karyopharm, Ionis, Disc, Deciphera, Geron, Janssen, Blueprint, Cogent, Novartis, Kartos, Telios, Ajax (now Lilly) |
| Pankit Vachhani, MD | Consulting or Advisory Role: Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, DISC medicine, Incyte, Sobi, Genentech, Geron, GlaxoSmith Kline, Kartos, Karyopharm, Merck, Novartis, Pharmaessentia, Prelude Therapeutics, Silence Therapeutics, Stemline, Servier, Syndax, Takeda; Board member: Alabama Cancer Congress |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Andrew Grzybowski, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, COO of Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, General Manager of Med Learning Group, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Chris Drury, Medical Director for Med Learning Group, has nothing to disclose.
- Melissa Johnson, Program Director for Med Learning Group, has nothing to disclose.
- Millena Papastavrou, Associate Program Manager for Med Learning Group, has nothing to disclose.
- Evan Hooper, Program Coordinator for Med Learning Group, has nothing to disclose.
- Russie Allen Russie Allen M.M., Accreditation & Outcomes Manager, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, dietary, physical, etc). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: October 09, 2026
EXPIRATION DATE: October 09, 2027
Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
